SCHEDULE: T. Rowe Price Discloses Zimmer Biomet Stake

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4.1% of Zimmer Biomet Holdings Inc. common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, indicating their beneficial ownership of Zimmer Biomet Holdings Inc. common stock.
• As of March 31, 2026, T. Rowe Price Associates, Inc. beneficially owns 7,997,806 shares of common stock.
• This represents 4.1% of the total class of securities.
• The filing is made under Rule 13d-1(b), classifying T. Rowe Price Associates, Inc. as an investment adviser.
• The company explicitly denies beneficial ownership, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of ownership by an institutional investor and does not contain performance data or strategic insights that would strongly influence sentiment.

Positives

• T. Rowe Price Associates, Inc. holds a significant stake (4.1%) in Zimmer Biomet Holdings Inc., suggesting confidence from a major investment firm.
• The filing is routine for institutional investors and indicates ongoing investment activity.

Negatives

• The filing explicitly denies beneficial ownership, which could imply a passive investment or a lack of intent to influence management.
• The filing does not provide any specific performance metrics or strategic insights from T. Rowe Price regarding Zimmer Biomet.

Risks

• The filing does not explicitly mention any risks.
• As a Schedule 13G filing, it primarily reports ownership and does not delve into operational or market risks of the issuer.

Future Outlook

This filing does not contain forward-looking statements or guidance from T. Rowe Price Associates, Inc. regarding Zimmer Biomet Holdings Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard for institutional investors reporting significant ownership stakes. T. Rowe Price's disclosure of a 4.1% stake in Zimmer Biomet indicates a substantial investment by a major asset manager within the medical device industry.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's stake, which can be viewed positively as a sign of confidence, but the explicit denial of beneficial ownership may temper expectations of active influence.
• Management of Zimmer Biomet Holdings Inc.: The filing indicates T. Rowe Price is a significant shareholder, but the denial of beneficial ownership suggests they are not seeking to influence control, which may be a neutral to positive signal for current management.
• Other Investors: The transparency provided by the filing allows other investors to assess the ownership structure and the presence of major institutional holders.

Next Steps

• Continue to monitor future SEC filings from T. Rowe Price Associates, Inc. for any changes in their stake in Zimmer Biomet Holdings Inc.
• Monitor Zimmer Biomet Holdings Inc. filings for any strategic updates or financial performance reports.

Key Dates

Keywords

Zimmer Biomet Holdings Inc., T. Rowe Price Associates, Inc., Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Institutional Investor